533 related articles for article (PubMed ID: 18812208)
21. 3Beta-alkyl-androsterones as inhibitors of type 3 17beta-hydroxysteroid dehydrogenase: inhibitory potency in intact cells, selectivity towards isoforms 1, 2, 5 and 7, binding affinity for steroid receptors, and proliferative/antiproliferative activities on AR+ and ER+ cell lines.
Ngatcha BT; Laplante Y; Labrie F; Luu-The V; Poirier D
Mol Cell Endocrinol; 2006 Mar; 248(1-2):225-32. PubMed ID: 16359782
[TBL] [Abstract][Full Text] [Related]
22. 17Beta-hydroxysteroid dehydrogenase Type 1 and Type 2: association between mRNA expression and activity in cell lines.
Day JM; Tutill HJ; Newman SP; Purohit A; Lawrence HR; Vicker N; Potter BV; Reed MJ
Mol Cell Endocrinol; 2006 Mar; 248(1-2):246-9. PubMed ID: 16490301
[TBL] [Abstract][Full Text] [Related]
23. 17Beta-hydroxysteroid dehydrogenases in human endometrium and its disorders.
Ito K; Utsunomiya H; Suzuki T; Saitou S; Akahira J; Okamura K; Yaegashi N; Sasano H
Mol Cell Endocrinol; 2006 Mar; 248(1-2):136-40. PubMed ID: 16406263
[TBL] [Abstract][Full Text] [Related]
24. The role of the heterocycle in bis(hydroxyphenyl)triazoles for inhibition of 17beta-Hydroxysteroid Dehydrogenase (17beta-HSD) type 1 and type 2.
Al-Soud YA; Bey E; Oster A; Marchais-Oberwinkler S; Werth R; Kruchten P; Frotscher M; Hartmann RW
Mol Cell Endocrinol; 2009 Mar; 301(1-2):212-5. PubMed ID: 18848601
[TBL] [Abstract][Full Text] [Related]
25. 17beta-hydroxysteroid dehydrogenase Type 1, and not Type 12, is a target for endocrine therapy of hormone-dependent breast cancer.
Day JM; Foster PA; Tutill HJ; Parsons MF; Newman SP; Chander SK; Allan GM; Lawrence HR; Vicker N; Potter BV; Reed MJ; Purohit A
Int J Cancer; 2008 May; 122(9):1931-40. PubMed ID: 18183589
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of inhibitors for 17beta-hydroxysteroid dehydrogenase type 1 in vivo in immunodeficient mice inoculated with MCF-7 cells stably expressing the recombinant human enzyme.
Husen B; Huhtinen K; Poutanen M; Kangas L; Messinger J; Thole H
Mol Cell Endocrinol; 2006 Mar; 248(1-2):109-13. PubMed ID: 16406284
[TBL] [Abstract][Full Text] [Related]
27. Estrone C15 derivatives--a new class of 17beta-hydroxysteroid dehydrogenase type 1 inhibitors.
Messinger J; Husen B; Koskimies P; Hirvelä L; Kallio L; Saarenketo P; Thole H
Mol Cell Endocrinol; 2009 Mar; 301(1-2):216-24. PubMed ID: 19014997
[TBL] [Abstract][Full Text] [Related]
28. Oxidations of 17beta-estradiol and estrone and their interconversions catalyzed by liver, mammary gland and mammary tumor after acute and chronic treatment of rats with indole-3-carbinol or beta-naphthoflavone.
Ritter CL; Prigge WF; Reichert MA; Malejka-Giganti D
Can J Physiol Pharmacol; 2001 Jun; 79(6):519-32. PubMed ID: 11430590
[TBL] [Abstract][Full Text] [Related]
29. Gender differences of enzymatic activity and distribution of 17beta-hydroxysteroid dehydrogenase in human skin in vitro.
Hikima T; Maibach HI
Skin Pharmacol Physiol; 2007; 20(4):168-74. PubMed ID: 17396051
[TBL] [Abstract][Full Text] [Related]
30. Discovery of a non-estrogenic irreversible inhibitor of 17β-hydroxysteroid dehydrogenase type 1 from 3-substituted-16β-(m-carbamoylbenzyl)-estradiol derivatives.
Maltais R; Ayan D; Trottier A; Barbeau X; Lagüe P; Bouchard JE; Poirier D
J Med Chem; 2014 Jan; 57(1):204-22. PubMed ID: 24328103
[TBL] [Abstract][Full Text] [Related]
31. Development of hormone-dependent prostate cancer models for the evaluation of inhibitors of 17beta-hydroxysteroid dehydrogenase type 3.
Day JM; Tutill HJ; Foster PA; Bailey HV; Heaton WB; Sharland CM; Vicker N; Potter BV; Purohit A; Reed MJ
Mol Cell Endocrinol; 2009 Mar; 301(1-2):251-8. PubMed ID: 18786604
[TBL] [Abstract][Full Text] [Related]
32. Synthesis and biological evaluation of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitors based on a thieno[2,3-d]pyrimidin-4(3H)-one core.
Lilienkampf A; Karkola S; Alho-Richmond S; Koskimies P; Johansson N; Huhtinen K; Vihko K; Wähälä K
J Med Chem; 2009 Nov; 52(21):6660-71. PubMed ID: 19824648
[TBL] [Abstract][Full Text] [Related]
33. 17beta-hydroxysteroid dehydrogenase 14 affects estradiol levels in breast cancer cells and is a prognostic marker in estrogen receptor-positive breast cancer.
Jansson AK; Gunnarsson C; Cohen M; Sivik T; Stål O
Cancer Res; 2006 Dec; 66(23):11471-7. PubMed ID: 17145895
[TBL] [Abstract][Full Text] [Related]
34. Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases.
Frotscher M; Ziegler E; Marchais-Oberwinkler S; Kruchten P; Neugebauer A; Fetzer L; Scherer C; Müller-Vieira U; Messinger J; Thole H; Hartmann RW
J Med Chem; 2008 Apr; 51(7):2158-69. PubMed ID: 18324762
[TBL] [Abstract][Full Text] [Related]
35. Effect of Medrogestone on 17beta-hydroxysteroid dehydrogenase activity in the hormone-dependent MCF-7 and T-47D human breast cancer cell lines.
Chetrite GS; Ebert C; Wright F; Philippe JC; Pasqualini JR
J Steroid Biochem Mol Biol; 1999 Jan; 68(1-2):51-6. PubMed ID: 10215037
[TBL] [Abstract][Full Text] [Related]
36. Biochemical and biological evaluation of novel potent coumarin inhibitor of 17β-HSD type 1.
Starčević S; Kocbek P; Hribar G; Rižner TL; Gobec S
Chem Biol Interact; 2011 May; 191(1-3):60-5. PubMed ID: 21232530
[TBL] [Abstract][Full Text] [Related]
37. Design, synthesis and biological evaluation of bis(hydroxyphenyl) azoles as potent and selective non-steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases.
Bey E; Marchais-Oberwinkler S; Kruchten P; Frotscher M; Werth R; Oster A; Algül O; Neugebauer A; Hartmann RW
Bioorg Med Chem; 2008 Jun; 16(12):6423-35. PubMed ID: 18514529
[TBL] [Abstract][Full Text] [Related]
38. Contribution to the development of inhibitors of 17β-hydroxysteroid dehydrogenase types 1 and 7: key tools for studying and treating estrogen-dependent diseases.
Poirier D
J Steroid Biochem Mol Biol; 2011 May; 125(1-2):83-94. PubMed ID: 21182944
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of type 2 17beta-hydroxysteroid dehydrogenase by estradiol derivatives bearing a lactone on the D-ring: structure-activity relationships.
Bydal P; Auger S; Poirier D
Steroids; 2004 May; 69(5):325-42. PubMed ID: 15219411
[TBL] [Abstract][Full Text] [Related]
40. A 3D QSAR model of 17beta-HSD1 inhibitors based on a thieno[2,3-d]pyrimidin-4(3H)-one core applying molecular dynamics simulations and ligand-protein docking.
Karkola S; Lilienkampf A; Wähälä K
ChemMedChem; 2008 Mar; 3(3):461-72. PubMed ID: 18224704
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]